Compare DUKR & ACXP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DUKR | ACXP |
|---|---|---|
| Founded | 2014 | 2017 |
| Country | Israel | United States |
| Employees | 4 | N/A |
| Industry | Aerospace | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.2M | 5.8M |
| IPO Year | 2015 | 2021 |
| Metric | DUKR | ACXP |
|---|---|---|
| Price | $1.46 | $1.05 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $10.33 |
| AVG Volume (30 Days) | 27.8K | ★ 94.2K |
| Earning Date | 11-16-2026 | 11-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $377,000.00 | N/A |
| Revenue This Year | $430.50 | N/A |
| Revenue Next Year | $245.00 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 249.07 | N/A |
| 52 Week Low | $1.45 | $0.90 |
| 52 Week High | $7.41 | $7.54 |
| Indicator | DUKR | ACXP |
|---|---|---|
| Relative Strength Index (RSI) | 10.87 | 46.16 |
| Support Level | N/A | $0.95 |
| Resistance Level | $5.85 | $1.12 |
| Average True Range (ATR) | 0.57 | 0.09 |
| MACD | -0.13 | 0.01 |
| Stochastic Oscillator | 0.96 | 62.81 |
DUKE Robotics Corp is a robotics company dedicated to developing a robotics stabilization system that enables remote, real-time, pinpoint accurate firing of small arms and light weapons as well as other civilian applications, with an emphasis in the field of routine infrastructure maintenance. The company offers high-voltage insulator washing abilities using its Insulator Cleaning (IC) Drone system. This technology provides an efficient and safe method for cleaning high-voltage insulators, improving their performance, enhancing safety, and reducing maintenance costs. It operates in one operating and reportable segment, the drone insulators washing activity.
Acurx Pharmaceuticals Inc is a late-stage biopharmaceutical company focused on developing a new class of small-molecule antibiotics for difficult-to-treat bacterial infections. Its approach is to develop antibiotic candidates with a Gram-positive selective spectrum (GPSS) that block the active site of the Gram-positive specific bacterial enzyme deoxyribonucleic acid (DNA) polymerase IIIC (pol IIIC), inhibiting DNA replication and Gram-positive bacterial cell death. Its research and development pipeline includes antibiotic product candidates targeting Gram-positive bacteria, including Clostridioides difficile, methicillin-resistant Staphylococcus aureus, vancomycin-resistant Enterococcus, and drug-resistant Streptococcus pneumoniae and B. anthracis. It operates in a single segment.